Objective: The Protein Production, Monoclonal Antibody, Tissue Culture Shared Resource (PPSR) supports basic and translational research at UCCC with validated cell lines, preparation of hybridomas, production of monoclonal antibodies, isolation and titering of baculovirus expressing recombinant proteins, and large scale preparation of recombinant proteins and monoclonal antibodies. Services &Technologies: PPSR provides assays pertinent to cancer research, including generation of hybridomas with desired properties to novel antigens, production of monoclonal antibodies, production of recombinant baculovirus that express proteins of interest, large scale cultivation of cells of varying types, and validated tumor cell lines known to be free of contaminants. In FY2010, 74 human tumor cell lines have been validated for use by UCC investigators. The facility has biosafety cabinets, tissue culture incubators, an ELISA plate reader, bioreactors including three GE Wave bioreactors for large scale cultivation of cells, refrigerators, freezers, and liquid nitrogen storage systems for maintaining stocks of cell lines. Consultation &Training: PPSR provides consultation and technical support to help members prepare and isolate hybridomas that produce monoclonal antibodies with the desired properties directed against their proteins of interest. The facility also provides consultation and technical support for preparation, isolation, and production of recombinant baculovirus vectors encoding proteins of interest to support biochemical, molecular, and structural studies by UCCC members, including large volume (0.5 to 10 I) cultures of insect cells producing the protein of interest. Validated tumor cell lines are maintained by the PPSR allowing UCCC investigators to utilize cell lines known to reflect the original tumor cell line, and to be free of contaminating species, in their research. Utilization: PPSR has served 48 UCCC members from all 6 Programs and 3 consortium institutions. The majority of the reagents and cell lines provided by the PPSR support multiple basic and translational projects. Management and Finances: This resource is UCCC-managed. 61% of the operating budget comes from charge backs to UCCC users who represent 76% of the total users. PPSR requests ~$300K CCSG support for 48% of its operating budget. This increase represents the continuation of the cell line validation service currently supported by ARRA funding. Increased funding will continue our ability to meet the needs of the cancer research community to generate and utilize recombinant proteins, monoclonal antibodies, and provide the community with validated tumor cell lines free of contaminants for use in basic and translational research programs.

Public Health Relevance

The Protein Production / Monoclonal Antibody / Tissue Culture Shared Resource provides a centralized services to make cancer-related proteins for UCCC members to study their mechanism of action in identified drugs and cancer-related biomarkers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-26
Application #
8616657
Study Section
Subcommittee G - Education (NCI)
Project Start
2014-02-05
Project End
2017-01-31
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
26
Fiscal Year
2014
Total Cost
$136,832
Indirect Cost
$47,643
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Harder, Bryan; Tian, Wang; La Clair, James J et al. (2017) Brusatol overcomes chemoresistance through inhibition of protein translation. Mol Carcinog 56:1493-1500
Chen, Yufei; Anastassiadis, Konstantinos; Kranz, Andrea et al. (2017) MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia. Cancer Cell 31:755-770.e6
DeRyckere, Deborah; Lee-Sherick, Alisa B; Huey, Madeline G et al. (2017) UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models. Clin Cancer Res 23:1481-1492
Scarborough, Hannah A; Helfrich, Barbara A; Casás-Selves, Matias et al. (2017) AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition. Clin Cancer Res 23:1531-1541
Neelakantan, Deepika; Zhou, Hengbo; Oliphant, Michael U J et al. (2017) EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nat Commun 8:15773
Barón, Anna E; Kako, Severine; Feser, William J et al. (2017) Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer. J Thorac Oncol 12:1512-1523
Todd, Maria C; Langan, Thomas A; Sclafani, Robert A (2017) Doxycycline-Regulated p16MTS1 Expression Suppresses the Anchorage-Independence and Tumorigenicity of Breast Cancer Cell Lines that Lack Endogenous p16. J Cancer 8:190-198
Brown, Dustin G; Borresen, Erica C; Brown, Regina J et al. (2017) Heat-stabilised rice bran consumption by colorectal cancer survivors modulates stool metabolite profiles and metabolic networks: a randomised controlled trial. Br J Nutr 117:1244-1256
Haverkos, Bradley M; Abbott, Diana; Hamadani, Mehdi et al. (2017) PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood 130:221-228
Shearn, Colin T; Saba, Laura M; Roede, James R et al. (2017) Differential carbonylation of proteins in end-stage human fatty and nonfatty NASH. Free Radic Biol Med 113:280-290

Showing the most recent 10 out of 1448 publications